Replies to post #748648 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

FYI I spoke with NICE in September and was told:

Thank you for your email regarding whether the company evidence submission will be published on our website.

A copy of the company evidence submission is made available on our website prior to publication of technology appraisal guidance. In line with our usual processes, confidential information would be redacted from the document before publication.

The evidence submission forms part of the committee papers which we make available on our website at the time that we publish either draft guidance or final draft guidance. Committee papers for this appraisal would be published on the project documents page.

Draft guidance will only be produced if the recommendations from the evaluation committee do not recommend use of the technology or limit the use of the technology beyond the specifications in the marketing authorisation. This outlined in the overview.

I hope this information is helpful.

Kind regards

[FeMike]

If it transpires that in the 26 months between November 2022 when the phase 3 trial results were first published and now management has not been seriously addressing the price of DCVax-L with NICE, my faith in them will be destroyed.

As far as I am concerned, if that transpires they will have a serious case to answer as to whether or not they are guilty of dereliction of their duty (or whatever the legalese might be).

Prepare yourself for disappointment, my friend.

NICE reimbursement isn't happening for at least 6 months following approval, probably not in 2025.

[learningcurve2020]

So the skeptics here which you proclaim to be “Disgusting specimens” might be right after all. Got it.

>>otherwise that will enable those disgusting specimens of humanity who infest this board (and others) to continue with their disgraceful agenda.

If it transpires that in the 26 months between November 2022 when the phase 3 trial results were first published and now management has not been seriously addressing the price of DCVax-L with NICE, my faith in them will be destroyed.

As far as I am concerned, if that transpires they will have a serious case to answer as to whether or not they are guilty of dereliction of their duty (or whatever the legalese might be).

[flipper44]

There is the cancer drug fund possibility. A large pharma recently used CDF funding to provide further data/treatments to demonstrate cost/benefit analysis weighed in their favor, and again, I think, in our unique situation, funding could be used (let’s say 45 million for a year as a guess) to run parallel testing on Eden to provide enough data to demonstrate cost/benefit analysis weighs in DCVax-L’s favor.

[Investor082]

They will dangle more carrots! They had a ton of time to prepare for NICE evidence since TLD release in May 2022. They should have submitted NICE evidence in parallel with MHRA application in Dec 2023 or soon thereafter in Q1 2024. All they had to do was hire another set of consultants for NICE reimbursement justification alongside MHRA consultants they hired in 2022 and 2023. They didn’t do that in 2022 or 2023. That tells you all need to know.

The fact that LP finally said they roped in consultants for NICE in Q3, 2024 also provides some clue that the big pharma is not interested in commercializing L. So LP is forced to go alone. Not good either way!